A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study
P Müller(Leiden University Medical Center), R. ten Cate(Leiden University), I. Brederije(Leiden University Medical Center), D. M. C. Brinkman(Leiden University), D. Schonenberg(Emma Kinderziekenhuis), Y. Koopman-Keemink(Juliana Kinderziekenhuis), W. Peter Bekkering(Leiden University Medical Center), J. Merlijn van den Berg(Boston Children's Hospital), Marion A. J. van Rossum(Reade), Taco W. Kuijpers(Sanquin), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), Cornelia F Allaart(Leiden University Medical Center)
Cited by 43
Related Papers
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease
|Nature Genetics|2011|355
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis
|Annals of the Rheumatic Diseases|2008|217